Owing to the complexity of the GVHD disease, the patients are often taking several medications ranging from immunosuppressive drugs, antibiotics, anti-inflammatory, corticosteroids, and analgesics [4] . Post HCT, it is vital that the rehabilitation team are aware of the key drugs, their interaction profiles and adverse effects since many drugs are known to have a negative influence on the MSK performance of the patients. The current paper outlines some of the most commonly used drugs and their side effects from MSK point of view.
Calcineurin inhibitors
The calcineurin inhibitors (CNI), i.e., cyclosporine A, and tacrolimus are powerful immunosuppressive agents aimed for prevention of GVHD in patients receiving allogeneic hematopoietic HCT [5] . Several studies have reported doserelated varying adverse effects on the MSK from cyclosporine (Table 1) . Isolated musculoskeletal pain in the ankles, feet, knees, wrists, shoulders, elbows, or metacarpophalangeal joints, 'leg bone pain syndrome' have been reported with CNI's and in some cases, patients having to use crutches to walk have been observed [6, 7] . Interestingly, in one of the case report, once tacrolimus was suspended owing to the suspicion of CNI induced pain syndrome (alternatively mycophenolic acid and steroid therapy were commenced), a subsequent profound improvement in the clinical picture was observed. From the above few cases, it is evident that the role of physical therapy [PT] would have been limited in such patients, but the knowledge about the drugs and their adverse effects would have helped the therapist direct the patient to the right care resulting in early intervention, thereby reducing the burden of the disease on the patient. 
Systemic corticosteroids
Topical steroid alone is generally indicated for Grade I aGVHD, and systemic corticosteroids remain the mainstay of first-line treatment in grade II-IV aGVHD starting with prednisolone or Methylprednisolone [8] . If the GVHD symptoms are worsening in any organ over 3 days of treatment or there is no response to steroid therapy in 5-14 days, secondary line treatment is usually considered [9] . There are multiple side effects of the use of steroids such as immunosuppression, osteopenia, oedema, muscle atrophy, skin atrophy, and impaired wound healing (long-term use) [10] . Vertebral fractures because of increased osteocyte and osteoblast death by apoptosis and inhibition of osteoblast generation is another important feature which the rehabilitation specialists need to be aware of where a patient might complain of non-resolving persisting back pain [11] . Lastly, avascular necrosis is one of the most debilitating adverse effects, which typically happens within a couple of years of HCT [12] .
mTOR inhibitors
Dose-dependent sirolimus has been associated with side effects like disabling joint pain and oedema particularly in the legs [13, 14] and in some worse cases leading to kneejoint necrosis requiring knee replacement [15] .
Proteasome inhibitors
Proteasome inhibition with agents, such as bortezomib and ixazomib, have assumed a central role in the management of multiple myeloma but has been used for both prevention and treatment of cGVHD [16] . The most common adverse effects of bortezomib (a proteasome inhibitor) from MSK point of view include: Dose-dependent bortezomib-induced peripheral neuropathy affecting the hands and legs with burning and tingling pain in the legs has been reported for between 55 to 70% of the patients in various studies [17, 18] and the author's placing emphasis on the importance of knowledge and monitoring of any new or worsening symptoms or signs of neuropathy in patients on bortezomib therapy.
Caution must be exerted by the PT with patients under bortezomib when administering rehabilitation sessions as patients treated with bortezomib have shown to have a reduction in the platelet count by an average of 60% during the first 14 days of treatment and can take up to 21 days to recover [19] . Several studies have suggested that reduced platelet count is a contraindication or precaution for patients performing exercises [20] .
JAK inhibitors
Ruxolitinib is an oral inhibitor of the JAK-1 and JAK-2 tyrosine kinases. Some of the common side effects seen in patients included fatigue, dizziness and muscle cramps [21] and one study reported a high incidence of anaemia and worsening of cytopenia [22] . However, it must be noted that these side effects were only at Grade I-II and short-lived, and cytopenia as a result of ruxolitinib was treatable with dose reduction and/or interruptions [23] .
Tumor necrosis factor (TNF) alpha-blockers (etanercept, infliximab, and adalimumab) Some of the side effects related to patient's on TNF drugs include neurological problems, new onset or exacerbation of central nervous system demyelinating disorders [24] , new onset or exacerbation of seizure disorders, lupus [25] , Guillain-Barre´syndrome [26] , paresis of the left facial nerve [27] 
BTK inhibitors
Ibrutinib is a BTK inhibitor, which was recently approved for use in steroid-refractory cGVHD by the United States Food and Drug Administration. Although there is a paucity of data on ibrutinib's direct effect on MSK in GVHD patients, it is well known that this drug can result in muscle cramps and myalgias [28] . Recently, spontaneous muscle haemorrhage was also reported owing to its use [29] .
Conclusions
It is imperative that transplant clinicians and rehabilitation professionals (particularly physical therapists) be familiar with the adverse effect profiles of common medications used in the treatment of GVHD, especially which impact the musculoskeletal function and overall rehabilitation. Guidelines are urgently needed to address many issues pertaining to PT in GVHD patients including platelet count cutoff, steroid myopathy, neutropenic risks, and neuropathy management.
Author contributions JM, TA, and SKH wrote the first draft of the manuscript. All authors contributed substantially to the conception, acquisition, analysis, and interpretation of the data for the work.
